The mission of our generics business is to make healthcare more affordable and to improve access to important medicines through the provision of high-quality small-molecule generics to patients all around the world. Currently our products are approved by regulatory agencies in around 100 countries and marketed through strategic partnerships and - in dedicated areas - through direct sales.

Innovative excellence

Complex small-molecule generics and hybrids form the backbone of our product portfolio. Our generic product range covers many therapeutic areas with medicines to treat a large number of diverse indications. One common factor drives our business and that is the pursuit of innovative excellence with a clear preference for complex synthesis and sophisticated dosage forms. This results in first-rate medicines that meet market needs, supported by strong patents that guarantee a long product lifespan. Our products are marketed at the earliest possible opportunity and sold at competitive prices.

Strategy

Synthon’s strategy from its inception included development of a vertically integrated organization for small-molecule generics, controlling every facet of the development chain beginning with research, development and production of active pharmaceutical ingredients through to manufacture and sale of our drug products.

 Our generic pipeline is well-filled with research projects and pending regulatory applications.

At-work-Synthon-Argentina-2-01312e18.jpg
About generic medicines

Generic medicines (or: generics) are fully equivalent to the originator product in strength, route of administration, quality and performance characteristics, and intended use.

read more
At-work-Synthon-Czech-Republic-2-8bb5f2ce.jpg
Glatiramer

In 2016, Synthon successfully concluded the decentralized procedures for glatiramer acetate 20mg/mL, a therapeutically equivalent version of the orginator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS) in Europe.

read more
Adverse events

If you experience possible side effects associated with a Synthon product, we may be required to get in touch with you for further information. Please contact us to report an adverse event related to Synthon products by sending us an e-mail.

report adverse event

Press releases
12 Apr 2016

Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe

read more
03 Aug 2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

read more
Events
24 Oct 2017 - 26 Oct 2017 - Frankfurt, Germany

CPhl Worldwide 2017

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 42,000 visiting pharma professionals over three days.…

read more